Table II
In Vitro Cytotoxicity of the Platinum Compounds Against Selected Human Tumour Cell Lines
| Compounds | Carriers (non-leaving groups) | Leaving groups | IC50, µM | |
|---|---|---|---|---|
| A549 | SGC-7901 | |||
| 2NH3 | DISA | 1.54 ± 0.08 | 2.65 ± 0.16 | |
| DACH | DISA | 1.05 ± 0.05 | 2.93 ± 0.13 | |
| BAMID | DISA | 2.16 ± 0.11 | 2.93 ± 0.15 | |
| 2NH3 | thymotate | 0.89 ± 0.03 | 1.83 ± 0.09 | |
| DACH | thymotate | 1.49 ± 0.04 | 6.95 ± 0.62 | |
| BAMID | thymotate | 1.27 ± 0.07 | 2.64 ± 0.06 | |
| 2NH3 | DIPSA | 0.33 ± 0.03 | 7.63 ± 0.82 | |
| DACH | DIPSA | 0.28 ± 0.03 | 1.09 ± 0.06 | |
| BAMID | DIPSA | 1.80 ± 0.07 | 2.54 ± 0.34 | |
| Carboplatin | 2NH3 | CBDCA |
9.26 ± 0.25 | 16.34 ± 0.69 |
| Oxaliplatin | DACH | oxalate | 3.54 ± 0.18 | 7.77 ± 0.56 |
| SKI-2053R | BAMID | malonate | 3.56 ± 0.20 | 2.36 ± 0.07 |